Compare AstraZeneca plc (AZN) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Invesco S&P 500 Low Volatility ETF — how do they compare? AstraZeneca plc trades at $167 (market cap $253.13B), while Invesco S&P 500 Low Volatility ETF trades at $75.93. The key difference: AstraZeneca plc pays a 1.92% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SPLV | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | — |
52-Week High | $209.48 | $77.45 |
52-Week Low | $137.44 | $70.30 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
SPLV trades at $76.41, up 0.75% with a bullish technical signal from moving averages. The ETF provides exposure to 100 S&P 500 stocks with the lowest volatility, maintaining strong defensive characteristics with no calendar-year losses exceeding 5% historically. Recent market volatility has increased investor interest in low-volatility strategies as tech valuations remain stretched.
The outlook remains positive given ongoing market uncertainty and inflation concerns. SPLV's defensive positioning offers portfolio stability, though concentrated sector exposure and quarterly rebalancing present implementation risks. The ETF's $6.93 billion in assets demonstrates institutional confidence in its low-volatility approach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
